What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?
Sodium glucose cotransporter 2 (SGLT2) inhibitors act in the body independent of insulin level. Glucagon-like peptide-1 (GLP-1) receptor agonists, on the other hand, are insulin dependent. Both classes are observed to promote weight loss as a secondary outcome to reducing hyperglycemia. Little is known, though, about whether the different mechanisms of action produce additive or synergistic effects on weight.
Combination therapy with an SGLT2 inhibitor and a GLP-1 receptor agonist: